JP2025511382A5 - - Google Patents
Info
- Publication number
- JP2025511382A5 JP2025511382A5 JP2024559004A JP2024559004A JP2025511382A5 JP 2025511382 A5 JP2025511382 A5 JP 2025511382A5 JP 2024559004 A JP2024559004 A JP 2024559004A JP 2024559004 A JP2024559004 A JP 2024559004A JP 2025511382 A5 JP2025511382 A5 JP 2025511382A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- dose
- pharmaceutical composition
- subject
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22166585.4 | 2022-04-04 | ||
| EP22166585 | 2022-04-04 | ||
| PCT/EP2023/058608 WO2023194273A1 (en) | 2022-04-04 | 2023-04-03 | Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025511382A JP2025511382A (ja) | 2025-04-15 |
| JP2025511382A5 true JP2025511382A5 (https=) | 2026-04-02 |
Family
ID=81327202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024559004A Pending JP2025511382A (ja) | 2022-04-04 | 2023-04-03 | 抗ｃ５抗体クロバリマブの使用によるギラン－バレー症候群の処置または予防のための投与量および投与レジメン |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250236662A1 (https=) |
| EP (1) | EP4504774A1 (https=) |
| JP (1) | JP2025511382A (https=) |
| KR (1) | KR20240168984A (https=) |
| CN (1) | CN118974082A (https=) |
| AU (1) | AU2023249891A1 (https=) |
| CA (1) | CA3251880A1 (https=) |
| IL (1) | IL314751A (https=) |
| MX (1) | MX2024012073A (https=) |
| TW (1) | TW202404632A (https=) |
| WO (1) | WO2023194273A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9388235B2 (en) * | 2006-09-05 | 2016-07-12 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| DK3658184T5 (da) * | 2017-07-27 | 2024-08-26 | Alexion Pharma Inc | Højkoncentrerede anti-c5-antistofformuleringer |
| CR20220040A (es) * | 2019-07-31 | 2022-03-02 | Hoffmann La Roche | Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab |
-
2023
- 2023-03-30 TW TW112112361A patent/TW202404632A/zh unknown
- 2023-04-03 EP EP23717443.8A patent/EP4504774A1/en active Pending
- 2023-04-03 AU AU2023249891A patent/AU2023249891A1/en active Pending
- 2023-04-03 IL IL314751A patent/IL314751A/en unknown
- 2023-04-03 CN CN202380031438.3A patent/CN118974082A/zh active Pending
- 2023-04-03 CA CA3251880A patent/CA3251880A1/en active Pending
- 2023-04-03 JP JP2024559004A patent/JP2025511382A/ja active Pending
- 2023-04-03 WO PCT/EP2023/058608 patent/WO2023194273A1/en not_active Ceased
- 2023-04-03 KR KR1020247032946A patent/KR20240168984A/ko active Pending
-
2024
- 2024-09-30 MX MX2024012073A patent/MX2024012073A/es unknown
- 2024-10-03 US US18/905,654 patent/US20250236662A1/en active Pending